|Cancer Stem Cell News 5.29 July 27, 2016|
Scientists showed that a subpopulation of leukemic stem cells can utilize gonadal adipose tissue as a niche to support their metabolism and evade chemotherapy. [Cell Stem Cell]
The authors prospectively characterized leukemia stem cell populations from a well-defined cohort of patients with acute myelogenous leukemia at diagnosis and relapse to assess the impact of the disease course on these critical populations. [Blood]
The authors investigated the efficacy of combination therapy of copanlisib with an ABL tyrosine kinase inhibitors (TKIs) using BCR-ABL-positive cells. Although the effects of the ABL TKI treatment were reduced in the presence of the feeder cell line, HS-5, copanlisib inhibited cell growth. [Oncotarget]
Therapies that abrogate breast tumor-initiating cells (BTIC) activity are needed to achieve durable cures for breast cancer patients. To identify such therapies scientists used a sensitive assay to complete a high-throughput screen of small molecules, including approved drugs, with BTIC-rich mouse mammary tumor cell populations. [Oncotarget]
Researchers examined whether sex determining region Y-box 9 (SOX9) represents a new cancer stem cell marker, and whether osteopontin can be used as a surrogate marker of SOX9 in hepatocellular carcinoma. [Sci Rep]
Investigators showed that ABCG2 can actively drive expression of stem cell markers and self-renewal in glioma cells. Stem cell markers and self-renewal was enriched in cells with high ABCG2 activity, and could be specifically inhibited by pharmacological and genetic ABCG2 inhibition. [Sci Rep]
MiR-96 and miR-183 expression in nasopharyngeal carcinoma (NPC) cancer stem-like cell (CSC) was detected by qRT-PCR. Transient and stable transfection was performed in Epstein-Barr virus (EBV)-positive NPC C666-1 cells to examine the effects of ectopic expression of miR-96 and miR-183 on repressing cell growth and CSC properties. [BMC Cancer]
The authors tested the inhibitory effects of bruceantin on multiple myeloma-cancer stem cells growth derived from a human primary tumor, and to explore a mechanism of action underlying these effects. [Cancer Biol Ther]
Lung cancer stem cells were enriched by sphere-forming culturing and their stem‑like properties were assessed. The results indicated that the lung tumorospheres had enhanced proliferation, clonality, invasion and cisplatin‑resistance, and showed significantly increased expression levels of CD133 and breast cancer resistance protein (ABCG2). [Mol Med Rep]
Roughly 25 years ago TAL1 was identified in early hematopoietic cells and involved in leukemia. The authors review the wealth of knowledge gained since then on its physiological roles and mechanisms by which TAL1 ectopic expression contributes to leukemogenesis. They emphasize recent findings that shed light into the intricacies of TAL1 (epi)genetic regulation and the transcription network orchestrated by this major T-cell oncogene. [Leukemia]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
AbbVie and Bristol-Myers Squibb Company announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie’s investigational biomarker-specific antibody drug conjugate Rova-T in combination with Bristol-Myers Squibb’s Opdivo and Opdivo + Yervoy regimen as a treatment for relapsed extensive-stage small cell lung cancer. [AbbVie]
In the ICT-107 Phase III registrational trial 109 patients have been screened in the US and Canada, with plans to randomize qualifying patients once they have completed standard of care and are re-screened. In addition, clinical supplies for 12 patients have been manufactured. ImmunoCellular also reported that 56 clinical sites in the US and two sites in Canada have been activated, representing almost half the total number of the planned 120 sites for the trial. [ImmunoCellular Therapeutics, Ltd.]
Presidential candidates begin to make clear their stark differences on climate change, energy production and stem-cell research. [Nature News]
The European Union is beefing up protections for volunteers in Phase I clinical trials in the wake of a disastrous clinical study in Rennes, France, that resulted in the death of one volunteer and the hospitalization of five others. The European Medicines Agency (EMA) in London announced in a “concept paper” that it wants to improve strategies to identify and reduce risks in “first-in-human” studies on healthy volunteers. EMA is asking for input from stakeholders. [ScienceInsider]
Chinese scientists are on the verge of being first in the world to inject people with cells modified using the CRISPR–Cas9 gene-editing technique. A team led by Lu You, an oncologist at Sichuan University’s West China Hospital in Chengdu, plans to start testing such cells in people with lung cancer next month. [Nature News]
Recent bibliometrics show that the number of published scientific papers has climbed by 8–9% each year over the past several decades. In the biomedical field alone, more than 1 million papers pour into the PubMed database each year — about two papers per minute. [Nature Careers]
Exactly one month after Britain’s momentous decision to leave the European Union, around 4500 scientists and friends of science will assemble in Manchester, UK, for the opening of the EuroScience Open Forum, Europe’s largest interdisciplinary research conference. [Science]
NEW European Society for Medical Oncology (ESMO) Asia 2016 Congress
Visit our events page to see a complete list of events in the cancer stem cell community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.
Home Cancer Stem Cell News Volume 5.29 | Jul 27 2016